These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 9929497)

  • 1. Molecular and physical mechanisms of first-pass extraction.
    Hall SD; Thummel KE; Watkins PB; Lown KS; Benet LZ; Paine MF; Mayo RR; Turgeon DK; Bailey DG; Fontana RJ; Wrighton SA
    Drug Metab Dispos; 1999 Feb; 27(2):161-6. PubMed ID: 9929497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism.
    Thummel KE; O'Shea D; Paine MF; Shen DD; Kunze KL; Perkins JD; Wilkinson GR
    Clin Pharmacol Ther; 1996 May; 59(5):491-502. PubMed ID: 8646820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytochrome P-450 3A4: regulation and role in drug metabolism.
    Guengerich FP
    Annu Rev Pharmacol Toxicol; 1999; 39():1-17. PubMed ID: 10331074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nutrient effects on drug metabolism and action in the elderly.
    Welling P
    Drug Nutr Interact; 1985; 4(1-2):173-207. PubMed ID: 3908042
    [No Abstract]   [Full Text] [Related]  

  • 5. Intestinal first-pass metabolism by cytochrome p450 and not p-glycoprotein is the major barrier to amprenavir absorption.
    Dufek MB; Bridges AS; Thakker DR
    Drug Metab Dispos; 2013 Sep; 41(9):1695-702. PubMed ID: 23821186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin.
    Gorski JC; Jones DR; Haehner-Daniels BD; Hamman MA; O'Mara EM; Hall SD
    Clin Pharmacol Ther; 1998 Aug; 64(2):133-43. PubMed ID: 9728893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Drug metabolism in the small intestine--the significance for biological availability].
    Andersen VC; Sonne J
    Ugeskr Laeger; 2000 May; 162(22):3215-9. PubMed ID: 10850220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of human intestinal first-pass metabolism of 25 CYP3A substrates from in vitro clearance and permeability data.
    Gertz M; Harrison A; Houston JB; Galetin A
    Drug Metab Dispos; 2010 Jul; 38(7):1147-58. PubMed ID: 20368326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gut Wall Metabolism. Application of Pre-Clinical Models for the Prediction of Human Drug Absorption and First-Pass Elimination.
    Jones CR; Hatley OJ; Ungell AL; Hilgendorf C; Peters SA; Rostami-Hodjegan A
    AAPS J; 2016 May; 18(3):589-604. PubMed ID: 26964996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The species differences of intestinal drug absorption and first-pass metabolism between cynomolgus monkeys and humans.
    Takahashi M; Washio T; Suzuki N; Igeta K; Yamashita S
    J Pharm Sci; 2009 Nov; 98(11):4343-53. PubMed ID: 19230019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A critical analysis of the interplay between cytochrome P450 3A and P-glycoprotein: recent insights from knockout and transgenic mice.
    van Waterschoot RA; Schinkel AH
    Pharmacol Rev; 2011 Jun; 63(2):390-410. PubMed ID: 21490128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug interactions: Proteins, pumps, and P-450s.
    Shapiro LE; Shear NH
    J Am Acad Dermatol; 2002 Oct; 47(4):467-84; quiz 485-8. PubMed ID: 12271287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-function of cytochromes P450 and flavin-containing monooxygenases: implications for drug metabolism.
    Halpert JR; Domanski TL; Adali O; Biagini CP; Cosme J; Dierks EA; Johnson EF; Jones JP; Ortiz de Montellano P; Philpot RM; Sibbesen O; Wyatt WK; Zheng Z
    Drug Metab Dispos; 1998 Dec; 26(12):1223-31. PubMed ID: 9860932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The oral route for the administration of cytotoxic drugs: strategies to increase the efficiency and consistency of drug delivery.
    Bardelmeijer HA; van Tellingen O; Schellens JH; Beijnen JH
    Invest New Drugs; 2000 Aug; 18(3):231-41. PubMed ID: 10958591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction of drugs and nutrition.
    Basu TK
    J Hum Nutr; 1977 Dec; 31(6):449-58. PubMed ID: 412897
    [No Abstract]   [Full Text] [Related]  

  • 16. Fentanyl metabolism by human hepatic and intestinal cytochrome P450 3A4: implications for interindividual variability in disposition, efficacy, and drug interactions.
    Labroo RB; Paine MF; Thummel KE; Kharasch ED
    Drug Metab Dispos; 1997 Sep; 25(9):1072-80. PubMed ID: 9311623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methodology for development of a physiological model incorporating CYP3A and P-glycoprotein for the prediction of intestinal drug absorption.
    Badhan R; Penny J; Galetin A; Houston JB
    J Pharm Sci; 2009 Jun; 98(6):2180-97. PubMed ID: 18855913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Species differences in intestinal metabolic activities of cytochrome P450 isoforms between cynomolgus monkeys and humans.
    Nishimuta H; Sato K; Mizuki Y; Yabuki M; Komuro S
    Drug Metab Pharmacokinet; 2011 Jun; 26(3):300-6. PubMed ID: 21383522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytochrome P450 3A4 in vivo ketoconazole competitive inhibition: determination of Ki and dangers associated with high clearance drugs in general.
    Boxenbaum H
    J Pharm Pharm Sci; 1999; 2(2):47-52. PubMed ID: 10952769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intestinal drug transporter expression and the impact of grapefruit juice in humans.
    Glaeser H; Bailey DG; Dresser GK; Gregor JC; Schwarz UI; McGrath JS; Jolicoeur E; Lee W; Leake BF; Tirona RG; Kim RB
    Clin Pharmacol Ther; 2007 Mar; 81(3):362-70. PubMed ID: 17215845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.